https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-06-01 / Cancer Res. 2006 Jun;66(11):5910-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-06-01 / Cancer Res. 2006 Jun;66(11):5910-82006-06-01 00:00:002019-02-15 09:17:03Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-06-01 / Prostate 2006 Jun;66(8):811-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-06-01 / Prostate 2006 Jun;66(8):811-212006-06-01 00:00:002019-02-15 09:24:16Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-06-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006 Jun;31(3):350-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-06-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006 Jun;31(3):350-22006-06-01 00:00:002006-06-01 00:00:00[Therapeutic effect of whole body hyperthermia combined with chemotherapy in patients with advanced cancer]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-06-01 / Expert Opin Biol Ther 2006 Jun;6(6):591-604
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-06-01 / Expert Opin Biol Ther 2006 Jun;6(6):591-6042006-06-01 00:00:002006-06-01 00:00:00Dendritic cell immunotherapy for breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-05-25 / Gene Ther. 2006 Oct;13(19):1391-402
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-05-25 / Gene Ther. 2006 Oct;13(19):1391-4022006-05-25 00:00:002019-02-15 08:50:22HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-05-24 / Biomed. Pharmacother. 2006 Jun;60(5):227-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-05-24 / Biomed. Pharmacother. 2006 Jun;60(5):227-322006-05-24 00:00:002006-05-24 00:00:00Analysis of cell proliferation and cell death during in situ hyperthermic treatment of neoplastic cells: a case report of human non-Hodgkin lymphoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-05-15 / J. Immunol. 2006 May;176(10):6065-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-05-15 / J. Immunol. 2006 May;176(10):6065-752006-05-15 00:00:002019-02-15 08:37:40Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-05-15 / Int. J. Cancer 2006 May;118(10):2617-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-05-15 / Int. J. Cancer 2006 May;118(10):2617-272006-05-15 00:00:002019-02-15 09:19:52Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-05-12 / Cancer Immunol. Immunother. 2006 Nov;55(11):1420-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-05-12 / Cancer Immunol. Immunother. 2006 Nov;55(11):1420-52006-05-12 00:00:002019-02-15 08:44:40Virology- and immunology-based gene therapy for cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-05-05 / Cancer Gene Ther. 2006 Oct;13(10):905-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-05-05 / Cancer Gene Ther. 2006 Oct;13(10):905-182006-05-05 00:00:002019-02-15 09:19:46Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
